Mouse Multiclonal Bcl-XL antibody. N-terminal. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human BCL2L1 aa 1-50.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 99% PBS, 0.05% BSA
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1-2 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1-2 µg/mL | Notes Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA buffer, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes. |
Select an associated product type
Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). Isoform Bcl-X(S) promotes apoptosis.
BCL2L1
BCL2L, BCLX, BCL2L1, Bcl-2-like protein 1, Bcl2-L-1, Apoptosis regulator Bcl-X
Mouse Multiclonal Bcl-XL antibody. N-terminal. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human BCL2L1 aa 1-50.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 99% PBS, 0.05% BSA
ab201335 shows no cross-reaction with Bax protein. ab201335 reacts with both Bcl-XS and Bcl-XL isoforms.
Purified from Bioreactor Concentrate.
What is an oligoclonal antibody?
This oligoclonal antibody is a cocktail of monoclonal antibodies that have been carefully selected. Oligoclonal antibodies have not only the specificity and batch-to-batch consistency of a monoclonal antibody, but also have the advantage of the sensitivity of a polyclonal antibody due to their ability to recognize multiple epitopes on an antigen.
Bcl-XL also known as Bcl-xL or Bcl-Xl protein is a member of the Bcl-2 protein family playing an important role in regulating cell death. Bcl-XL inhibits apoptosis by binding to pro-apoptotic proteins preventing the release of cytochrome c from mitochondria. This protein has a molecular weight of approximately 30 kDa. Bcl-xL is widely expressed in tissues notably in the brain endothelial cells and hematopoietic tissues where it contributes to cell survival.
This protein acts as an anti-apoptotic molecule within the mitochondria and is part of the Bcl-2 family complex. Bcl-XL modulates the balance between pro-apoptotic and anti-apoptotic signals impacting cell fate. By binding and sequestering pro-apoptotic members such as Bax and Bak Bcl-XL prevents mitochondrial outer membrane permeabilization important for avoiding programmed cell death. This function not only supports cellular longevity but also understanding cancer cell survival.
The Bcl-XL protein holds a significant position in the apoptotic signaling pathways. It is particularly involved in the intrinsic pathway where its interactions with mitochondrial proteins Bax and Bak determine cell survival or death. It is interconnected with the PI3K/AKT pathway where AKT kinase activity can upregulate Bcl-XL expression demonstrating how survival signals are transmitted. These interactions highlight its pivotal role in balancing life and death at the cellular level.
Bcl-XL's overexpression often connects to the progression of cancers and resistance to chemotherapy. By inhibiting programmed cell death Bcl-XL allows cancer cells to evade traditional treatments. Furthermore research implicates Bcl-XL in neurodegenerative disorders where its interaction with Bcl-2 proteins disrupts normal apoptotic processes contributing to cellular dysfunction and disease. Understanding Bcl-XL's disease-related roles furthers the development of targeted therapies combating its protective effects in pathological contexts.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-Bcl-XL antibody [BX006 + 2H12] - N-terminal (ab201335) at 1 µg/mL
All lanes: Jurkat cell lysate
Predicted band size: 26 kDa
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human Hodgkin's lymphoma tissue labeling Bcl XL with ab201335 at 1μg/ml.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com